Holding(s) in Company

RNS Number : 7619S

SkinBioTherapeutics PLC

18 March 2021

 

SkinBioTherapeutics plc

Significant Shareholder

Manchester, UK - 18 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, provides an update on the shareholding of OptiBiotix Health Plc ("OptiBiotix") in the Company.

As part of the Placing and Open Offer announced 30 October 2020, the Company, OptiBiotix and Cenkos Securities plc ("Cenkos"), entered into a lock-in and orderly market agreement pursuant to which OptiBiotix agreed to certain undertakings. On 12 March 2021 OptiBiotix approached the Company and Cenkos seeking consent to sell two million shares in the Company. Noting the high demand for SBTX shares, the Company and Cenkos consented to the sale of the shares subject to maintaining an orderly market.

Consequent to the disposal of shares, OptiBiotix's holding in the Company has reduced to 36,138,569 shares representing 23.2% of the issued share capital.

All parties are committed to maintaining the terms of the lock-in agreement for the remainder of its term and there is no expectation that a further consent request will be made by or granted to OptiBiotix.

TR-1: S tandard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :			SkinBioTherapeutics plc Company No: 09632164 (England)
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligation iv
Name			Optibiotix Health PLC
City and country of registered office (if applicable)			York (UK)
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi :			17 March 2021
6. Date on which issuer notified (DD/MM/YYYY):			18 March 2021
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached	23.18			23.18	155,889,922
Position of previous notification (if applicable)	24.46			24.46

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary		36,138,569					23.18
SUBTOTAL 8. A		36,138,569					23.18
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash settlement xii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Change due to sale of shares

Place of completion	Edinburgh
Date of completion	18 March 2021

 

-Ends-

 For more information, please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	Tel: [phone] [e-mail]

 

END

 

 

HOLJPMITMTMBBBB